Transcode Therapeutics (RNAZ) Research & Development (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Research & Development came in at $5.1 million in Q1 2026, up 130.09% YoY from $2.2 million in Q1 2025, and down 6.73% on a QoQ basis from $5.5 million in Q4 2025.
Transcode Therapeutics (RNAZ) Research & Development (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Research & Development data on file, last reported at $5.1 million in Q1 2026.
- Quarterly Research & Development rose 130.09% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.3 million (up 60.42% YoY) and the FY2025 annual result came in at $13.4 million, up 38.28% from the prior year.
- Research & Development slipped to $5.1 million in Q1 2026, from $5.5 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $5.5 million in Q4 2025 to a low of $1.2 million in Q3 2024.
- A 5-year average of $3.0 million and a median of $3.0 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 1137.31% — and 2024, when it plunged 63.28%.
- Tracing RNAZ's Research & Development over 5 years: stood at $2.7 million in 2022, then climbed by 25.19% to $3.4 million in 2023, then gained by 8.17% to $3.6 million in 2024, then soared by 50.49% to $5.5 million in 2025, then declined by 6.73% to $5.1 million in 2026.
- The last three Research & Development figures came in at $5.1 million (Q1 2026), $5.5 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 3.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.11 Mn |
| Dec 31, 2025 | 5.48 Mn |
| Sep 30, 2025 | 3.16 Mn |
| Jun 30, 2025 | 2.57 Mn |
| Mar 31, 2025 | 2.22 Mn |
| Dec 31, 2024 | 3.64 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Jun 30, 2024 | 3.08 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Dec 31, 2023 | 3.36 Mn |
| Sep 30, 2023 | 3.34 Mn |
| Jun 30, 2023 | 2.97 Mn |
| Mar 31, 2023 | 2.59 Mn |
| Dec 31, 2022 | 2.69 Mn |
| Sep 30, 2022 | 3.04 Mn |
| Jun 30, 2022 | 2.62 Mn |
| Mar 31, 2022 | 1.88 Mn |
| Dec 31, 2021 | 1.29 Mn |
| Sep 30, 2021 | 992,946.00 |
| Jun 30, 2021 | 211,752.00 |